ALKS|Alkermes Plc|Price:34.910|Chg%:1.36

More Details of Alkermes Plc Company

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc Info



Ticker SymbolALKS

Company nameAlkermes Plc

IPO dateJul 16, 1991

CEOPops (Richard F)

Number of employees1800

Security typeOrdinary Share

Fiscal year-endJul 16

AddressConnaught House

CityDUBLIN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryIreland

Postal codeD04 C5Y6

Phone35317728000

Websitehttps://www.alkermes.com/

Ticker SymbolALKS

IPO dateJul 16, 1991

CEOPops (Richard F)

Company Executives of Alkermes Plc



Name

Name/Position

Position

Shareholding

Change

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+1119.00%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

57.74K

-4000.00%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+6089.00%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+6089.00%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+2508.00%

Ms. Nancy S. Lurker

Independent Director

10.71K

+6089.00%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Mr. C. Todd Nichols

Senior Vice President, Chief Commercial Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+1119.00%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

57.74K

-4000.00%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+6089.00%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+6089.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

VIVITROL

121.13M

30.73%

LYBALVI

98.25M

24.92%

ARISTADA

98.05M

24.87%

Royalty Revenue - VUMERITY

32.12M

8.15%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.18M

7.66%

Other

14.46M

3.67%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

VIVITROL

121.13M

30.73%

LYBALVI

98.25M

24.92%

ARISTADA

98.05M

24.87%

Royalty Revenue - VUMERITY

32.12M

8.15%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.18M

7.66%

Other

14.46M

3.67%

Shareholding Stats

Updated: Sat, Jan 31

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

14.33%

The Vanguard Group, Inc.

10.87%

T. Rowe Price Associates, Inc.

6.09%

State Street Investment Management (US)

5.17%

Baker Bros. Advisors LP

4.90%

Other

58.64%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

14.33%

The Vanguard Group, Inc.

10.87%

T. Rowe Price Associates, Inc.

6.09%

State Street Investment Management (US)

5.17%

Baker Bros. Advisors LP

4.90%

Other

58.64%

Shareholder Types

Shareholders

Proportion

Investment Advisor

55.16%

Investment Advisor/Hedge Fund

28.21%

Hedge Fund

17.62%

Pension Fund

2.33%

Research Firm

2.18%

Individual Investor

1.48%

Sovereign Wealth Fund

1.18%

Bank and Trust

0.43%

Private Equity

0.42%

Institutional Shareholding



Updated: Mon, Dec 8

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

744

175.23M

117.54%

-23.12K

2025Q3

767

175.30M

122.16%

+2.11M

2025Q2

769

173.38M

125.62%

-4.15M

2025Q1

759

177.46M

124.05%

-27.05M

2024Q4

734

172.08M

130.58%

-12.03M

2024Q3

705

184.36M

134.23%

-884.11K

2024Q2

687

185.17M

126.42%

+3.87M

2024Q1

659

181.61M

124.10%

-28.36M

2023Q4

633

182.01M

111.83%

+12.84M

2023Q3

601

169.31M

104.05%

+9.33M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

23.65M

14.33%

-72.87K

-0.31%

Sep 30, 2025

The Vanguard Group, Inc.

18.13M

10.98%

-325.52K

-1.76%

Sep 30, 2025

T. Rowe Price Associates, Inc.

10.05M

6.09%

+189.56K

+1.92%

Sep 30, 2025

State Street Investment Management (US)

8.54M

5.17%

+332.10K

+4.05%

Sep 30, 2025

Baker Bros. Advisors LP

8.09M

4.9%

+1.68M

+26.22%

Sep 30, 2025

Renaissance Technologies LLC

6.29M

3.81%

+482.37K

+8.30%

Sep 30, 2025

American Century Investment Management, Inc.

4.40M

2.66%

+740.25K

+20.24%

Sep 30, 2025

Geode Capital Management, L.L.C.

4.06M

2.46%

+37.84K

+0.94%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

3.70M

2.24%

+601.36K

+19.42%

Sep 30, 2025

JP Morgan Asset Management

3.62M

2.19%

-326.93K

-8.29%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

AdvisorShares Psychedelics ETF

7.31%

iShares Neuroscience and Healthcare ETF

3.82%

First Trust NYSE Arca Biotechnology Index Fund

3.3%

Invesco S&P SmallCap Health Care ETF

3.1%

ALPS Medical Breakthroughs ETF

2.07%

Knowledge Leaders Developed World ETF

1.69%

Langar Global HealthTech ETF

1.44%

State Street SPDR S&P Biotech ETF

1.35%

Abacus FCF International Leaders ETF

1.34%

Invesco S&P SmallCap Quality ETF

1.32%

AdvisorShares Psychedelics ETF

Proportion7.31%

iShares Neuroscience and Healthcare ETF

Proportion3.82%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.3%

Invesco S&P SmallCap Health Care ETF

Proportion3.1%

ALPS Medical Breakthroughs ETF

Proportion2.07%

Knowledge Leaders Developed World ETF

Proportion1.69%

Langar Global HealthTech ETF

Proportion1.44%

State Street SPDR S&P Biotech ETF

Proportion1.35%

Abacus FCF International Leaders ETF

Proportion1.34%

Invesco S&P SmallCap Quality ETF

Proportion1.32%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data